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The primary event in mammalian sexual development is the differentiation of the bipotential gonads into either testes or ovaries. Our
understanding of the molecular pathways specifying gonadal differentiation is still incomplete. To identify the initial molecular changes
accompanying gonadal differentiation in mice, we have performed a large-scale transcriptional analysis of XX and XY Sf1-positive gonadal cells
during sex determination. In both male and female genital ridges, a robust genetic program is initiated pre-dating the first morphological changes
of the differentiating gonads. Between E10.5 and E13.5, 2306 genes were expressed in a sex-specific manner in the somatic compartment of the
gonads; 1223 were overexpressed in XX embryos and 1083 in XY embryos. Although sexually dimorphic genes were scattered throughout the
mouse genome, we identified chromosomal regions hosting clusters of genes displaying similar expression profiles. The cyclin-dependent kinase
inhibitors Cdkn1a and Cdkn1c are overexpressed in XX gonads at E11.5 and E12.5, suggesting that the increased proliferation of XY gonads
relative to XX gonads may result from the overexpression of cell cycle inhibitors in the developing ovaries. These studies define the major
characteristics of testicular and ovarian transcriptional programs and reveal the richness of signaling processes in differentiation of the bipotential
gonads into testes and ovaries.
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Gonadal development is unique in embryology because a
common precursor, the bipotential gonad, can assume two
divergent fates, forming either testes or ovaries. In mice, the
bipotential gonads arise shortly before embryonic day 10.5, as
evidenced by a thickening of the coelomic epithelium adjacent
to the mesonephros; they contain somatic cells and primordial
germ cells (Brennan and Capel, 2004; McLaren, 2003).
Commitment of the bipotential gonad to form testes is dictated0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Sex-determining region, Y chromosome. SRY encodes a DNA
binding protein of the high mobility group (HMG) box family
that is both necessary and sufficient to direct testis determina-
tion (Koopman et al., 1991). In the absence of SRY, both XX
and XY gonads develop along the ovarian pathway (Capel et
al., 1993). Sry expression in the XY gonads starts at the 11–12
tail somite (ts) stage just after embryonic day 10.5 (E10.5) and
peaks at 18 ts (E11.5), 36 h prior to the earliest histologic
evidence of testis differentiation and finally declines towards
28 ts (E12.5) (Bullejos and Koopman, 2001; Hacker et al.,
1995; Jeske et al., 1995). In a cell-autonomous fashion, Sry
promotes male development by directing the supporting cell
lineage to form Sertoli cells instead of follicular cells (Palmer87 (2005) 361 – 377
www.e
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turn, initiate cellular and morphological changes such as testis
cord formation, migration of cells from the mesonephros,
vascularization and Leydig cell differentiation (for review, see
Brennan and Capel, 2004).
Although the cellular processes of male sexual differentia-
tion have been studied extensively, the specific molecular
mechanisms by which gonads are formed and, in particular, the
nature of the cascade of putative transcriptional events initiated
by Sry remain poorly understood. Key regulators of develop-
ment of the bipotential gonad in both sexes include steroido-
genic factor 1 (SF1), Wilm’s tumor 1 (WT1), Lhx9 and Emx2
(for review, see Capel, 2000). In the case of Sf1 null mice,
gonadal development is initiated, but the gonadal primordium
regresses by apoptosis at E12.5, indicating that Sf1 is required
for the differentiation and/or the maintenance and growth of the
somatic cells in the developing gonad (Luo et al., 1994). Over
the past years, several key regulators of the male pathway have
been identified. These include Sox9 (Kent et al., 1996; Morais
da Silva et al., 1996), Dmrt1 (Raymond et al., 1998, 2000),
Fgf9 (Colvin et al., 2001), Dhh (Bitgood et al., 1996), Sox8
(Chaboissier et al., 2004) and Dax1 (Meeks et al., 2003).
However, the molecular pathogenesis of 46 XY gonadal
dysgenesis, 46 XY male to female sex reversal or 46 XX true
hermaphroditism remains enigmatic in more than 75% of
patients, suggesting that other genes affecting sex determina-
tion are yet to be discovered (see review by Cotinot et al.,
2002).
One of the earliest consequences of Sry expression is
increased proliferation of somatic cells, resulting in a dramatic
increase in the size of embryonic testes relative to ovaries.
Treatment of E11 mice with proliferation inhibitors blocks the
formation of testis cords and male sex differentiation, establish-
ing the essential role of this increased cell proliferation in the
male pathway (Schmahl and Capel, 2003). However, the
identity of the proteins mediating the XY-specific proliferation
or the XX-specific quiescence of the differentiating gonads
remains elusive.
Insights into the molecular events in early ovarian
development are even more rudimentary. For more than 50
years, female development was considered the ‘‘default’’
pathway due largely to the observation that SRY triggers the
male pathway, while the female pathway proceeds in the
absence of male-promoting signals. A current model of
female sex determination suggests that the stable commitment
to the ovarian pathway occurs when the germ cells enter
meiosis (Yao et al., 2003). The autonomous entry of the germ
cells into meiosis initiates the ovarian pathway and blocks
testis development. SRY opposes this pathway by initiating
cord formation prior to meiosis, thereby sequestering germ
cell inside testis cords and blocking meiosis. Although a
female-determining gene analogous to SRY has not been
identified, it is obvious that a specific program of ovarian
organogenesis is somehow triggered. Unfortunately, very little
is known about the molecular regulation of early ovarian
development. Only a handful of genes with a female-specific
expression have been linked directly to the earliest events inovarian development and function: follistatin (Shimasaki et
al., 1989), Wnt4 (Vainio et al., 1999), Bmp2 (Zhang and
Bradley, 1996), Dax1 (Swain et al., 1996) and GDF9 (Elvin
et al., 1999a,b). Thus, there is a compelling need to define
additional genes that mediate ovarian development and to
define molecular milestones that herald specific stages in
these processes.
In view of the differential development of the bipotential
gonad in response to a single genetic switch (i.e., the presence
of absence of SRY), gonadal development provides an
excellent opportunity to identify genes involved in differential
organogenesis. Genes with sexually dimorphic expression
patterns have been identified by either differential display
(Tohonen et al., 1998), subtractive hybridization (McClive
and Sinclair, 2003; Menke and Page, 2002) or cDNA
microarrays (Grimmond et al., 2000; Smith et al., 2003).
Due to technical limitations, these experiments assayed only a
small fraction of the transcriptome and were performed at
stages (E12.5 and E13.5) when testicular or ovarian differen-
tiation is already well underway. In addition, they included
both the somatic and the germ cell compartments of the
developing gonads. The goal of the present study was to
identify and characterize the transcriptional changes in
somatic cells that accompany the differentiation of the
bipotential gonads into either testes or ovaries. We surveyed
the expression profile of approximately 34,000 genes in the
somatic compartments of XX and XY gonads prior to, during
and after sex determination (E10.5–E13.5) and identified a
large number of genes that exhibit sexually dimorphic
expression before the first morphological changes of the
differentiating gonad. We have thus defined the major
characteristics of distinct transcriptional programs within the
somatic compartments of male and female gonads that
underlie testicular and ovarian differentiation.
Materials and methods
Isolation of Sf1/eGFP-positive cells and RNA extraction
C57/B6 CBAJ female mice were bred with Sf1/eGFP transgenic male
mice. The mice were maintained on a 12L:12D cycle. Adult females were
time-mated and checked for the presence of vaginal plugs the next morning
(day post-coitum 0.5). On the relevant days of gestation (dpc 10.5, 11.0, 11.5,
12.5 and 13.5), pregnant females were sacrificed, and the presence of the Sf1/
eGFP transgene in the embryos was assessed under a fluorescent binocular
microscope for the presence of strong GFP fluorescence in the urogenital
ridges. Urogenital ridges from individual embryos were dissected, digested
with trypsin/EDTA and filtered through a 40 Am cell strainer to generate
single cell suspensions. GFP-positive cells were sorted using a FACS Vantage
SE, collected in 96-well plates containing 50 Al of RNA lysis buffer from
Qiagen RNeasy kit and stored at 70-C until needed. Accurate staging of
embryos between 10.5 and 12.5 dpc was performed by counting the tail
somites (ts). Embryos at 8 ts (T2 ts) were considered as E10.5, 14 ts (T2 ts) as
E11.0, 19 ts (T2 ts) as E11.5 and 30 ts (T3 ts) as E12.5. Routine sexing of the
embryos was performed by PCR to check for the presence or the absence of
two Y-chromosome-specific genes Sry (15,869: 5V CAG CCC TAC AGC
CAC ATG AT 3V; 15,870: 5V GAG TAC AGG TGT GCA GCT CTA 3V) and
Zfy (16,541: 5V CAG AAC CCT TTG GTA CAC TG 3V; 16,542: 5V AAC
ACC ACT CTC AAG AGT AG 3V). GFP-positive cells were pooled
according to the developmental stage and genetic sex of each embryo. Total
RNAs were extracted using RNeasy micro kit from Qiagen according to the
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RNA 6000 nanochips with an Agilent 2100 bioanalyzer.
RT-PCR assays performed with 120 ng of totRNAs from male or female
cells at E13.5 that are positive or negative for GFP were used to assess cellular
specificity and purity of the GFP+ populations purified by FACS. Total RNAs
were reverse-transcribed with the Omniscript RT-kit from Qiagen according to
manufacturer’s instructions, and 1/20th of cDNA template was used as template
for each PCR reaction. Amplification of Gapdh, Sf1, Cyp11a, Insl3, AMH and
Oct4 was achieved with a classical 30 cycles program using the following
primers: Gapdh primers 15,024 5VTCC ATG ACA ACT TTG GCATTG 3V and
15,025 5V CAG TCT TCT GGG TGG CAG TGA 3V; Sf1 primers; 20,112 5V
AAA TTC CTG AAC AAC CAC AGC 3V; 20,113 5V GCA TCT CAA TGA
GAA GCT TG 3V; Cyp11a primers, 20,116 5V AGT GGC AGT CGT GGG
GAC AGT 3V; 20,117 5V TAA TAC TGG TGA TAG GCC GCC 3V; Insl3
primers, 15,725 5V CGG GAT CCA CCA TGC GCG CGC CGC TGC TA 3V;
15,726 5V TCA GTG GGG ACA CAG ACC CAA 3V; AMH primers, 20,130 5V
ACT GGG AGG AAC CCC TAT TA 3V; 20,131 5VGCG CAG ATC TAC ACT
CAG CT 3V; Oct4 primers, 20,114 5V CTC AGC CTT AAG AAC ATG TG 3V;
20,115 5V TTC TCT TGT CTA CCT CCC TT 3V; Irx3 primers, 20,193 5VGGA
CCA ACA GGC CTT TCC 3V; 20,194 5V CAC AAC GAA GGA ACC TCA
CA 3V.
Microarray probe labeling and hybridization
Approximately 50,000–100,000 GFP+ cells were needed to obtain the
minimum 50 ng of total RNA required for the generation of a single probe for
the Affymetrix GeneChip analysis. The numbers of embryos necessary for the
isolation of 100,000 cells are ¨20 at E10.5, ¨10 at E11.0 and E11.5 and
around 5 at E12.5 and E13.5. We employed a small-scale protocol from
Affymetrix to reproducibly amplify and label total RNA. In short, 50–100 ng
of RNAwas converted into double-stranded cDNA using a cDNA synthesis kit
(Superscript, Invitrogen) with a special oligo(dT)24 primer containing a T7
RNA promoter site added 5V to the poly(T) tract. Following the first cRNA
amplification by in vitro transcription (IVT) using the Ambion MEGAscript T7
kit, 400 ng of cRNA was once more reverse-transcribed, and biotinylated
cRNAs were generated from double-strand cDNAs using an IVT labeling kit
from Affymetrix. For each probe, 20 Ag of the 2nd amplification biotinylated
cRNA was fragmented and hybridized to Mouse Genome 430 2.0 Array
(Affymetrix, High Wycombe, UK) by using Affymetrix GeneChip Fluidics
Station 450 and standard protocols. For each condition, three independent sets
of totRNA were isolated and used as a template for probe generation. These
triplicates were performed to minimize the effects of biological variability. We
explored 5 different time points (E10.5, E11.0, E11.5, E12.5 and E13.5) either
with male or female Sf1-positive cells, thus requiring a total of 30 sets of 430
2.0 arrays. GeneChips were incubated at 45-C for 16 h with biotin-labeled
cRNAs probes and then washed and stained using a streptavidin–phytocoer-
ythrin (SAPE) conjugate with antibody amplification as described in
Affymetrix protocol.
Normalization
Prior to analysis, the data were normalized (scaled) to correct for variations
in mRNA/totRNA ratio, yield of the IVT, amounts of cRNA probe applied to
the microarrays, using the Affymetrix GCOS 1.1 software. Basically, the
output of each array was multiplied by a factor in order to make a robust
average equivalent to arbitrary target intensity (i.e., 100). The robust average
intensity of an array was calculated by averaging all the signal intensities on
the array, excluding the highest 2% and lowest 2% of the values. Normalized
values were then exported and analyzed with GeneSpring and Matlab. As a
complement, we carried out a Robust MultiArray Analysis (RMA) 3,4 using a
quantile normalization and analyzed the set data using GeneSpring software
(Silicon Genetics, Redwood City, CA) and Matlab 7* (Math Works, Inc.,
MA).
Selection of differentially expressed genes
To identify differentially expressed transcripts, pairwise comparison
analyses were carried out with Affymetrix GCOS 1.2. Each of the experimentalsamples (n = 3) was compared with each of the reference samples (n = 3),
resulting in nine pairwise comparisons. This approach, which is based on the
Mann–Whitney pairwise comparison test, allows the ranking of results by
concordance, as well as the calculation of significance (P value) of each
identified change in gene expression (Hubbell et al., 2002). Genes for which the
concordance in the pairwise comparisons exceeded a threshold (e.g., 60%) were
considered to be statistically significant. A 77% cutoff in consistency of change
(at least 7 of 9 comparisons were either increased or decreased) was then
applied to identify potential dimorphic-regulated genes. Only genes that
satisfied the pairwise comparison test and displayed 1.5-fold change in
expression were selected for further study. This conservative analytical
approach was used to limit the number of false-positives. Regulated genes
were organized and visualized into using the GeneSpring software (Silicon
Genetics, Redwood City, CA).
Gene clustering
Sexually dimorphic genes were clustered according to their expression in
the different mouse tissues by using the Matlab compiled version 3.3.20 version
of the super paramagnetic clustering (SPC) algorithm (Blatt et al., 1996; Getz
et al., 2000). Before each clustering operation, the expression values were
normalized using RMAexpress version 0.3 (http://stat-www.berkeley.edu/users/
bolstad/RMAExpress/RMAExpress.html), RMAexpress is a GUI version of the
RMA, which is the Robust Multichip Average (Bolstad et al., 2003; Irizarry
et al., 2003). It consists of three steps: a background adjustment, quantile
normalization and finally summarizations measured is log2 expression value,
then log2 expression value was centered and normalized for each genes at the
end of the process, the average of each gene will be 0, and its standard
deviation equal to 1 as described (Liu et al., 2002).
Chromosome analysis
The chromosomal analysis has been performed using Matlab programming
language. The Chromosomal position of the Affymetrix probe set was obtained
from the Affymetrix website (http://www.affymetrix.com), the length of each
chromosome was obtained from the Ensembl website (www.ensembl.org). For
a selected gene, we draw a bar at a position along a line representing the
chromosome length. Probe sets specifically enriched in male and female were
represented with blue and red bars, respectively.
Whole-mount in situ hybridization (WISH)
Whole-mount in situ hybridization was carried out as described (Gerard et
al., 1996). Briefly, gonads were dissected in PBS, fixed overnight in 4%
paraformaldehyde at 4-C, washed in PBS, and then dehydrated in graded
methanol solution and store at 20-C in 100% methanol until needed.
Plasmids containing cDNAs of the relevant candidate genes were linearized
and then used as template to generate digoxigenin-labeled antisense ribop-
robes. Expression profiles were analyzed at E10.5, E11.5, E12.5 and E13.5
using at least two pairs of embryos of each sex at each stage per candidate
gene.
Depletion of germ cells by busulfan treatment
Gonads depleted of germ cells were generated by injecting pregnant
females with 50 mg/kg busulfan at 9.5 dpc and then harvesting embryos at
E13.5. The germ cell marker Oct4 was used as probe to check that germ cells
were completely depleted using WISH (Figs. 3C and D).
Immunohistochemistry
Embryos at E10.5, E11.5, E12.5 and E13.5 were fixed overnight at 4-C in
4% paraformaldehyde/PBS, rinsed in PBS during the following day and finally
embedded in paraffin. Five-micrometer sections were incubated overnight at
4-C with a GFP antibody (Molecular Probes, 1/200). GFP was detected by
fluorescent imaging with an Alexa Fluor 488 goat anti-rabbit IgG (Molecular
Probes, 1/2000).
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Isolation of Sf1+ somatic cells from both male and female
genital ridges
To specifically isolate somatic cells from male and female
gonads, we used Sf1/eGFP transgenic mice expressing eGFP
under the control of 50 kb of the mouse steroidogenic factor 1
(Sf1) promoter (Stallings et al., 2002). Sf1 is expressed in the
somatic compartments of developing genital ridge of both male
and female embryos starting at E9.0 (Ikeda et al., 1994), both
in supporting cell precursors (future Sertoli and granulosa cells)
and steroidogenic cell precursors (future Leydig and theca
cells). In order to accurately determine which cells within theFig. 1. Expression of the Sf1/GFP transgene in the somatic compartment of the g
drawing of a E10.5 embryo with the genital ridges colored in green. (B) Bright
fluorescent photomicrograph (C) and the merged picture (D). (E) RT-PCR performed
(+) or negative () for GFP. As expected, GFP+ cells expressed Sf1 as well as soma
GFP immunohistochemistry indicates that GFP is exclusively expressed in the somat
(G, K), E12.5 (H, L) and E13.5 (I, M). Note the absence of GFP expression in ge
mesonephric tubules; MD, mu¨llerian ducts; GR, genital ridges; CE, coelomic epithXX and XY urogenital ridges express eGFP, we performed
immunohistochemistry (IHC) with an antibody against GFP on
Sf1/eGFP gonads at E10.5, E11.5, E12.5 and E13.5 (see Fig.
1). GFP was specifically expressed in the somatic compart-
ment, including the coelomic epithelium, of both XX and XY
gonads. Most somatic cells of genital ridges appeared to
express GFP, although there is a range of intensity of
expression: for example, Leydig cells tend to express more
GFP that Sertoli cells. In contrast, no signal was detected in
germ cells (see arrows in Fig. 1). Overall, the developmental
profile of the Sf1/eGFP transgene closely parallels the
expression of the endogenous Sf1 gene in the developing
gonads during the period of sex determination (E10.5–E12.5)
(see Fig. 1 and Stallings et al., 2002).enital ridge and the subsequent isolation of Sf1-positive cells. (A) Schematic
field view of a dissected Sf1 EGFP genital ridge at E10.5, its corresponding
with total RNAs from male (S) or female (9) cells at E13.5 that are positive
tic cell markers such as AMH, Insl3 or Irx3 but not the germ cell markers Oct4.
ic cells of male (F–I) and female (J–M) urogenital ridges at E10.5 (F, J), E11.5
rm cells (arrows). Scale bar: 50 Am. Abbreviations: WD, wolffian ducts; MT,
elium.
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were dissected then dissociated to produce single cell suspen-
sions and sorted into GFP+ and GFP population using a FACS
Vantage SE. We collected in average 5000 GFP+ cells from the
genital ridges of single embryos at E10.5. This number
increased to ¨10,000 at E11.0–E11.5, ¨18,000 at E12.5 and
¨25,000 at E13.5. At E13.5, the difference in size between XY
and XX gonads, caused by increased proliferation and cell
recruitment from the mesonephros, was visible, and we
obtained ¨25% more GFP+ cells from male genital ridges
than their female counterparts.
In control experiments, we found that cross contamination
of eGFP+ by eGFP cells was <2% (Supplementary Fig. 1). To
confirm cellular specificity, we compared gene expression
profiles of eGFP+ and eGFP pools at E13.5 by RT-PCR (Fig.
1E). Both male and female eGFP+ fractions expressed Sf1 but
not the male eGFP fraction, suggesting that we had
specifically isolated Sf1+ somatic cells. Indeed, classical
markers for male Sf1-positive cells, i.e., transcripts expressed
in Sertoli (AMH) and Leydig cells (Insl3, Cyp11a), were
detected in the male eGFP+ fraction, while the early somatic
ovarian marker Irx3 was expressed specifically in the female
eGFP+ fraction. As expected, Oct4, the germ cell marker, was
excluded from eGFP+ fractions, although a very faint band can
be observed in the male eGFP+ fraction. It is therefore formally
possible that highly expressed genes specifically expressed in
contaminating eGFP cells may be included in our list of
dimorphic genes.
Identification of male and female genetic programs
To identify the initial molecular changes associated with
testicular and ovarian differentiation, we selected 5 different
time points (E10.5, E11.0, E11.5, E12.5 and E13.5) for analysis
of male and female Sf1+ somatic cells. Gene expression
profiling was performed with high-density Affymetrix Gen-
eChip\ Mouse Genome 430 2.0 microarrays containing over
34,000 well-substantiated mouse genes. Each of the time points
was performed in triplicate to minimize the effect of biological
variability. A total of 30 separate arrays were used, and
microarray data including the expression profile of every
sexually dimorphic genes, chromosomal maps and hierarchical
clusterings are all conveniently accessible through the Nef
laboratory website at http://www.medecine.unige.ch/recherche/
research_groups/nef/. The entire database is also available via
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), a public
repository for microarray data from the European Bioinfor-
matics Institute and the Microarray Management and Analysis
System (MIMAS), a microarray data repository developed by
members of the Swiss Array Consortium (SAC) (http://
www.mimas.unibas.ch).
We found that almost half of the probe sets/genes (47%)
contained on the Affymetrix microarrays were expressed by the
Sf1+ cell population, 10% of these (2306 genes) exhibited a
sexually dimorphic expression. Among the 2306 genes display-
ing 1.5-fold differences between the somatic compartment of
male and female gonads during the critical stages of gonadaldetermination, 1083 of these were upregulated in the male gonad
and 1223 in female gonad (Fig. 2). For simplicity, the terms
‘‘gene’’ and ‘‘probe set’’ are used synonymously, although this is
not totally accurate since some genes are represented more than
one time by different probe sets on the array. At E10.5,
corresponding to the onset of Sry expression in XY genital
ridges, only 14 genes displayed a dimorphic expression in
somatic cells of the gonads: 8 were expressed at a higher level in
males and 6 in females. Twelve hours later, male upregulated
genes increased to 11, while female upregulated genes remained
at 6. At the peak of Sry expression (E11.5), dimorphic genes
increased to 86: 61 were upregulated in males and 25 in females.
Genes specifically upregulated in males and females numbered
592 and 546 respectively at E12.5 and almost doubled to 919 in
males and 1029 in females by E13.5.
Male and female transcriptomes prior to gonadal
differentiation
Prior to gonadal determination (E10.5), only a handful of
genes exhibited sex-specific expression (see Table 1). At this
stage, all genes identified by our transcriptome analysis with
male-specific expression localize within a 1 megabase (Mb)
region on the Y chromosome (Smcy, Uty, Ddx3y, Eif2s3y),
while all genes with female-specific expression localize on the
X chromosome (Xist, Utx, Erdr1). Interestingly, out of the 1060
probe sets located on the X chromosome, 506 were expressed at
similar levels both in male and female gonads, while only 3
genes escaped X-inactivation and were upregulated in the
female. In contrast to Xist, a non-coding gene required for X
inactivation, and Utx (Greenfield et al., 1998; Heard, 2004), the
Erythroid differentiation factor 1 gene (Erdr1) (Dormer et al.,
2004) has never been reported to escape X inactivation. The
Erdr1 gene is located on the distal part of the X chromosome
(XqF5, BAC RP24-143B12). Classical and quantitative RT-
PCR experiments confirmed the female overexpression pattern
(approximately 2-fold) both in gonadal tissue at E10.5, E11.5,
E12.5 and E13.5 as well as in the brain and liver at E13.5 (data
not shown) which indicates that Erdr1 is broadly expressed and
escapes X inactivation. For all these X- and Y-specific genes
described above, sexually dimorphic expression was main-
tained at each developmental stage thereafter (data not shown).
Except for Erdr1, the dimorphic expression of these sex
chromosome-specific genes has also been reported in both
mouse (E10.5; Dewing et al., 2003) and human (Vawter et al.,
2004) brains, suggesting that their sexually dimorphic expres-
sion is not gonad-specific but is probably ubiquitous. The
absence of autosomal genes with a sex-dimorphic expression at
E10.5 is consistent with the fact that sex determination has not
yet occurred. From this perspective, the E10.5 data provide a
baseline to identify genes with a dimorphic expression at later
stages of gonadal development.
Identification of the male-specific genetic program
Twelve hours after the initiation of Sry expression (E11.0), 4
additional genes showed an overexpression in the somatic
Fig. 2. Global changes in gene expression during gonadal differentiation indicate that both male and female genetic programs are initiated as early as E11.5.
Scatterplot analysis representing the systematic comparison of the log2-scaled expression signals from male and female somatic transcriptomes at E10.5, E11.0,
E11.5, E12.5 and E13.5 (A–E). Blue dots represent genes with expression levels statistically similar both in male and female gonads, while red dots represent genes
whose expression profiles were found to be sexually dimorphic (>1.5-fold change, black diagonals). (F) Overall summary of sexually dimorphic genes during the
critical stages of sex determination.
S. Nef et al. / Developmental Biology 287 (2005) 361–377366compartment of the male gonads (see Supplementary Table 1).
These are: one IMAGE clone (Affymetrix ID 1455451), one
Riken clone (Affymetrix ID 1438511), the X-linked lympho-Table 1
Sexually dimorphic genes at E10.5
Gene name Gene symbol
Male enhanced gene expression (probe sets) at E10.5
Selected mouse cDNA on the Y Smcy
Eukaryotic translation initiation factor 2, subunit 3 Eif2s3y
DEAD (Asp–Glu–Ala–Asp) box polypeptide 3 Ddx3y
Ubiquitously transcribed tetratricopeptide repeat gene Uty
DEAD (Asp–Glu–Ala–Asp) box polypeptide 3 Ddx3y
DEAD (Asp–Glu–Ala–Asp) box polypeptide 3 Ddx3y
– , – , –
RIKEN clone:4930534N17
Female enhanced gene expression (probe sets) at E10.5
Inactive  specific transcripts Xist
Inactive  specific transcripts Xist
Inactive  specific transcripts Xist
Erythroid differentiation regulator 1 Erdr1
Erythroid differentiation regulator 1 Erdr1
Ubiquitously transcribed tetratricopeptide repeat gene Utxcyte-regulated 3a gene (Xlr3a, Affymetrix ID 1420357) and the
G-protein-coupled receptor 37 gene (Gpr37, Affymetrix ID
1450875). All four genes demonstrated a transient male-Affy ID GenBank Chromosome Fold change
1424903 AF127244 Y 33.47
1417210 NM_012011 Y 25.79
1426438 BB667072 Y 24.38
1426598 BB742957 Y 13.15
1452077 AA210261 Y 9.21
1426439 AJ007376 Y 7.47
1447329 AI506532 ? 4.75
1444668 AV268386 ? 5.77
1427262 L04961 X 61.97
1436936 BG806300 X 35.54
1427263 R74734 X 29.21
1439200 BE686792 X 2.29
1452406 AJ007909 X 2.24
1427235 AW536493 X 1.53
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Gpr37 gene, which encodes an orphan G-protein-coupled
receptor shown to be expressed in brain tissues and testis
(Marazziti et al., 1997, 1998). Increased expression of Gpr37 at
E11.0 and E11.5 in the male somatic compartment was
confirmed by whole-mount in situ hybridization (data not
shown).
At E11.5, a developmental stage corresponding to the peak
of Sry expression, we observed a dramatic increase in the
number of genes preferentially expressed in the male somatic
compartment: 61 genes had higher expression in male gonads
(see Table 2). These genes include early male markers such
as Sox9, Dhh or Fgf9 but also male-specific markers
previously identified at later stages of testicular differentiation
(Cst9, Spp1, Mmd2, Aard, Cbln1, Cbln4, Rgn). Numerous
genes with a male-specific expression have not previously
been described as sexually dimorphic, including the tran-
scription factor Etv5, an intracellular FGF receptor antagonist
Spry4 and the metalloproteinase Adamts16 (see Table 2 for
details).
At E12.5 and E13.5, the supporting cell precursors of the
male gonads have already differentiated in Sertoli cells, and the
fetal Leydig cells first appear in the developing testis. This
differentiation is consistent with a massive change in gene
expression: genes upregulated during testis determination
increased in number from 61 at E11.5 to 587 at E12.5 (see
Supplementary Table 2) to 919 at E13.5 (see Supplementary
Table 3). Concomitant with the appearance of Leydig cells
around E12.5 and E13.5, genes encoding enzymes involved in
steroidogenesis underwent a drastic, male-specific increase in
expression. This includes genes such as StAR (4- and 22-folds
higher in males versus females at E12.5 and E13.5 respective-
ly), Cyp11a1 (8- and 394-fold higher), Cyp17a1 (35- and 246-
fold higher), Cyp26b1 (12- and 45-fold higher), Hsd3b1 (12-
and 12-fold higher), Hsd11b2 (5- and 6-fold higher) and
Hsd17b7 (3-fold higher at E13.5).
To assess the efficiency of the transcriptome analysis at
identifying the genes upregulated in the somatic compartment
of testis, we scanned our data for genes known to be
expressed in Sertoli or/and Leydig cells. Our GeneChip
profile analysis detected all previously described male-
specific genes expressed at E11.5 and E12.5; this includes
genes such as Cystatin 9, AMH, Hedgehog interacting
protein (Hhip), Nexin1, Vanin 1, Insl3, Renin1, tescalcin,
Cyp26b1, Pak3, tdl, GDNF, Dtna, Patched and Maestro (see
Grimmond et al., 2000; Menke and Page, 2002; Smith et al.,
2003; Tohonen et al., 1998), with the notable exception of
Sry. To explore this apparent discrepancy, we performed
quantitative RT-PCR for Sry using as templates our 2nd
amplification biotinylated cRNAs used as probes for micro-
array labeling. As reported in the literature, we indeed
observed a strong peak of Sry expression at E11.5 in male
eGFP+ cells (data not shown). Thus, the Sry probe sets of the
430 2.0 microarray probably do not efficiently detect Sry
transcripts. Overall, the expression profiles of known male
markers were similar in our microarrays analyses to what
have been reported in the literature, further validating ourresults (see Supplementary Fig. 2). Of the 1083 genes
displaying an increased expression in somatic cells of
developing testes, only a few have been reported previously.
Taken together, these results suggest that we have identified
more than 1000 genes that had not as yet been associated
with testis differentiation and that these represent a large
proportion of the genes whose expression is male-specific in
gonadal somatic cells.
A robust female-specific genetic program is initiated as early
as E11.5
At both E10.5 and E11.0, only 6 genes located on the X
chromosome were overexpressed in the female somatic cells,
suggesting that differentiation of the female gonad has not yet
started. By E11.5, the initiation of a female-specific genetic
program was detected with the upregulation of 25 genes (see
Table 2). 24 h later, the number of genes upregulated during
ovarian development increased drastically, reaching 546 genes
at E12.5 and 1029 genes at E13.5 (see Supplementary Tables
2 and 3 respectively). The identification of this large cohort of
genes whose expression is upregulated during early ovarian
development constitutes a major, and somewhat unexpected,
finding and suggests that an important genetic program is
initiated within the somatic compartment of the developing
ovary well before the first histological evidence of ovarian
differentiation. To assess whether we achieved a complete
catalogue of the genes upregulated in the somatic compart-
ment of ovary, we scanned our transcriptome data for the
small number of genes reported to be expressed in female
gonad somatic cells. Our expression profile analyses detected
all of the genes known to be expressed in the somatic
compartment of the developing ovary at E11.5 and E12.5,
including Wnt4, follistatin (Shimasaki et al., 1989), Bmp2
(Zhang and Bradley, 1996) and Dax1 (Swain et al., 1998) (see
Supplementary Fig. 2). For more than 1000 of the female-
specific genes identified here, our data provide the first
evidence that they are expressed in somatic cells of the
developing female gonad.
The complex molecular mechanisms that establish gonadal
differentiation must be coordinated by modules or networks of
genes that share common function (e.g., proliferation, cellular
organization, etc). An example is given by the structural
proteins keratins, markers of tissue organization, that revealed
differences in their expression depending on the sex of the
gonads. In XX genital ridges, the first changes at the cellular
and structural level occur between E12 and E13.5 with the
formation of loose cord-like structures referred to as ovigerous
cords (Konishi et al., 1986; Odor and Blandau, 1969).
Ovigerous cords are composed of a cluster of primordial germ
cells surrounded by somatic cells with a mesenchymal
appearance. We found that keratins (K) 7, 8, 18 and 19 are
overexpressed in the developing ovaries from E11.5 onward
(data not shown). It has been shown previously that K8, K18
and K19 are expressed in the somatic compartment of the
ovigerous cords during fetal life and in primordial follicles
(Appert et al., 1998). These dimorphic expression profiles
Table 2
Sexually dimorphic genes at E11.5
Gene ID GenBank Gene symbol Gene name Chromosome Fold change
Male overexpressed genes (probe sets) at E11.5
1417210 NM012011 Eif2s3y Eukaryotic translation initiation factor 2, subunit 3 Y 256.00
1426438 BB667072 Ddx3y RIKEN cDNA 8030469F12 Y 126.04
1452077 AA210261 Ddx3y DEAD (Asp–Glu–Ala–Asp) box polypeptide 3 Y 49.64
1457582 BB528233 Uty Ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome Y 26.81
1426598 BB742957 Uty Ubiquitously transcribed tetratricopeptide repeat gene Y 25.40
1424903 AF127244 Smcy Selected mouse cDNA on the Y Y 20.95
1418744 NM021344 tesc Tescalcin 5 15.40
1426439 AJ007376 Ddx3y DEAD (Asp–Glu–Ala–Asp) box polypeptide 3 Y 12.41
1449285 NM009979 Cst9 Cystatin 9 2 7.18
1460693 BG074456 Col9a3 Procollagen, type IX, alpha 3 2 6.60
1420786 NM011253 RbmY1a1 RNA binding motif protein, Y chromosome, family 1, member A1 Y 6.30
1457945 BM121819 Mus musculus transcribed sequences ? 6.02
1460734 BG074456 Col9a3 Procollagen, type IX, alpha 3 2 6.02
1434959 AV367068 Dhh Desert hedgehog 15 4.96
1434528 AV256613 Aard Alanine- and arginine-rich domain containing protein 15 4.74
1444038 BI076720 Mus musculus transcribed sequence X 4.70
1438654 AV269411 Mmd2 Monocyte to macrophage differentiation-associated 2 5 4.00
1424950 BI077717 Sox9 SRY-box containing gene 9 11 3.76
1422247 NM009484 Uty Ubiquitously transcribed tetratricopeptide repeat gene,
Y chromosome
Y 3.73
1433607 AV343573 Cbln4 Cerebellin 4 precursor 2 3.56
1449254 NM009263 Spp1 Secreted phosphoprotein 1 5 3.51
1448852 NM009060 Rgn Regucalcin X 3.38
1451538 BC024958 Sox9 SRY-box containing gene 9 11 3.13
1445669 BB080456 Spry4 Sprouty homolog 4 18 2.89
1439604 AV319357 Adamts16 A disintegrin-like and metalloprotease with
thrombospondin type 1 motif, 16
13 2.70
1457270 AI506234 RIKEN cDNA B230343A10 11 2.66
1434653 AV026976 Ptk2b PTK2 protein tyrosine kinase 2 beta 14 2.64
1438718 AW046863 Fgf9 Fibroblast growth factor 9 14 2.58
1423287 AA016422 Cbln1 Cerebellin 1 precursor 8 2.56
1448021 AA266723 Mus musculus transcribed sequences 3 2.54
1423286 BQ174436 Cbln1 Cerebellin 1 precursor 8 2.50
1423288 AA016422 Cbln1 Cerebellin 1 precursor protein 8 2.35
1448330 NM010358 Gstm1 Glutathione S-transferase, mu 1 3 2.33
1418028 NM010024 Dct Dopachrome tautomerase 14 2.23
1447707 BB367174 Pde2a Phosphodiesterase 2A, cGMP-stimulated 7 2.23
1424393 BC026584 Adhfe1 Alcohol dehydrogenase, iron containing, 1 1 2.23
1425627 J03952 Gstm1 Glutathione S-transferase, mu 1 3 2.19
1453345 AK014427 RIKEN cDNA 3830408G10 4 2.19
1424392 BC026584 Adhfe1 Alcohol dehydrogenase, iron containing, 1 1 2.19
1433454 BB621938 Expressed sequence AW539457 2 2.18
1416416 NM010358 Gstm1 Glutathione S-transferase, mu 1 3 2.14
1449109 NM007706 Socs2 Suppressor of cytokine signaling 2 1 2.14
1434099 BB752393 Casp7 Caspase 7 1 2.14
1430943 AK020088 RIKEN cDNA 6030498E09 5 2.13
1418507 BB244736 Socs2 Suppressor of cytokine signaling 2 10 2.11
1428142 AK003461 Etv5 ets variant gene 5 4 2.08
1416411 NM008183 Gstm2 Glutathione S-transferase, mu 2 3 1.88
1433453 BB621938 Expressed sequence AW539457 2 1.88
1424477 BC019731 Hypothetical protein MGC30809 5 1.82
1450875 BQ175510 Gpr37 G-protein-coupled receptor 37 6 1.77
1416468 NM013467 Aldh1a1 Aldehyde dehydrogenase family 1, subfamily A1 19 1.75
1428834 AK012530 Dusp4 Dual specificity phosphatase 4 8 1.74
1418412 NM009413 Tpd52l1 Tumor protein D52-like 1 10 1.74
1436990 AA038464 RIKEN cDNA 1620401E04 10 1.68
1423858 BC014714 Hmgcs2 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 2 3 1.66
1418237 NM009929 Col18a1 Procollagen, type XVIII, alpha 1 10 1.64
1419072 NM026672 RIKEN cDNA 0610005A07 3 1.62
1448894 NM008012 Akr1b8 Aldo–keto reductase family 1, member B8 6 1.61
1450744 NM138953 Ell2 Elongation factor RNA polymerase II 2 13 1.56
1437132 BB535494 Nedd9 Neural precursor cell expressed, developmentally downregulated gene 9 13 1.54
1416600 AF260717 Dscr1 Down syndrome critical region homolog 1 16 1.54
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Gene ID GenBank Gene symbol Gene name Chromosome Fold change
Female overexpressed genes (probe sets) at E11.5
1427262 L04961 Xist Inactive  specific transcripts X 26.40
1436936 BG806300 Xist Inactive  specific transcripts X 16.89
1427263 R74734 Xist Inactive  specific transcripts X 11.76
1421365 NM008046 Fst Follistatin, Fst, NM_008046 // follistatin 13 6.65
1434458 BB444134 Follistatin 1 precursor 13 4.29
1420771 NM011470 Sprr2d Small proline-rich protein 2D 3 3.05
1418517 NM008393 Irx3 Iroquois related homeobox 3 8 2.99
1429814 AV232168 Mus musculus transcribed sequence 19 2.62
1416871 NM007403 Adam8 A disintegrin and metalloprotease domain 8 7 2.54
1439200 BE686792 Erdr1 Erythroid differentiation regulator 1 X 2.30
1457110 BB440150 Mus musculus transcribed sequences 19 2.26
1452406 AJ007909 Erdr1 Erythroid differentiation regulator 1 X 2.09
1415777 NM018874 Pnliprp1 Pancreatic lipase related protein 1 19 2.06
1428089 AK014285 RIKEN cDNA 3200001I04 14 2.03
1424638 AK007630 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 17 2.03
1451095 BC005552 Asns Asparagine synthetase 6 1.90
1419431 NM_007950 Ereg Epiregulin 5 1.87
1435155 BI455486 Cgn Cingulin 3 1.84
1433988 BG075755 RIKEN cDNA C230098O21 8 1.81
1433966 AV212753 Asns Asparagine synthetase 6 1.81
1436978 AV273409 Wnt9a Wingless-type integration site 9A 11 1.73
1440150 AI893889 Tgm3 Transglutaminase 3, E polypeptide 2 1.62
1437113 BM228590 Pld1 Phospholipase D1 3 1.62
1434170 BB083162 RIKEN cDNA A230038L21 X 1.61
1422804 NM011454 Serpinb6b Serine (or cysteine) proteinase inhibitor, clade B, member 6b 13 1.58
1456307 BB746807 Clone IMAGE:3596174 8 1.54
1452366 AV371987 RIKEN cDNA 4732435N03 8 1.53
Table 2 (continued)
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mediate proper development, differentiation and interaction of
the various cell types of the ovary.
Validation of expression profiles by RT-PCR and whole-mount
ISH
To confirm the expression profiles of sexually dimorphic
genes identified with our microarray analysis, we selected 26
genes (including equal proportions of male and female-
overexpressed clones, see Supplementary Table 4) for further
study. We performed either quantitative RT-PCR (data not
shown) and/or whole-mount in situ hybridization (WISH)
with XX and XY gonads at E10.5, E11.5, E12.5 and E13.5.
Whole-mount ISH was found to be more informative than
quantitative RT-PCR assays, mainly because it reveals the
spatio-temporal expression pattern of each selected gene. In
the case of male-specific candidates, WISH refined our
analysis by determining in which somatic cell types the
explored genes were expressed: expression within testicular
cords indicates a Sertoli-specific expression, while interstitial
expression suggests a Leydig-specific expression. Not only
were we able to confirm the sexual dimorphism between male
and female gonads (Figs. 3 and 6), but we also found that
expression profiles revealed by microarray analyses faithfully
reflected the expression profiles generated by quantitative RT-
PCR or WISH (Fig. 6). Overall, the analyses of these of 26
genes strikingly validated the expression profiles generated by
microarrays.To verify the somatic expression of this subset of testis and
ovarian genes, we analyzed their expression in E13.5 busulfan-
treated embryonic gonads. Exposure to busulfan completely
eliminates germ cells (Merchant, 1975), as confirmed in our
studies by the abrogation of expression of the germ cell marker
Oct4 (Figs. 3C and D). Busulfan treatment did not cause
marked changes in the expression of Cdkn1a, Daam2, Tcf12,
Runx1, Irx3 and Gpr49, in female gonads or of Cbln1, Cbln4,
Rerg, Tesc, Nedd9 and Gpr37 in male gonads, confirming the
somatic expression of these 14 genes and suggesting that it is
largely independent of the presence of germ cells. The
expression of Wnt9a appeared to be upregulated in busulfan-
treated female gonads, while Grb14 expression was down-
regulated, but not completely ablated, in male busulfan-treated
gonads. Thus, interactions between the germinal and the
somatic compartments may affect the expression of these two
genes; alternatively, Grb14 may be coexpressed by germ and
somatic cells.
Hierarchical clustering of dimorphic genes
To obtain a broad overview of the expression profiles of the
2306 sexually dimorphic genes, we generated a hierarchical
clustering of these genes. This yields a dendrogram that
arranges the genes in tight clusters according to similar patterns
of expression. Examination of the clusters showed that once
sexual dimorphism is initiated, the dimorphism remains at later
stages. In Fig. 4, we present a hierarchical clustering of the 88
probe sets that displayed a sexually dimorphic expression
Fig. 3. Validation of expression profiles by whole-mount ISH. A selection of 8 female (A) and 8 male (B) overexpressed genes initially identified by our transcriptome
analysis was selected, and overexpression either in ovary or testis was confirmed by WISH. To rule out germ cell-specific expression of candidate genes, expression of
7 female (C) and 7 male (D) overexpressed candidate genes was assessed in busulfan-treated testes (Sb) or ovaries (9b). Oct4, a germ-cell-specific marker, has been
used as an internal control to confirm germ cell depletion in busulfan-treated gonads. Embryonic stage is 13.5 except when otherwise noted.
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dimorphism a later stages. This analysis confirms previous
hypotheses formed by examination of gonadal expression ofknown male- or female-specific genes and indicates that only a
small subset of genes (e.g., Sry or Gpr37) exhibit a transient
pattern of sexually dimorphic expression.
Fig. 4. Hierarchical clustering of 88 probe sets with male or female dimorphism
at E11.5. Genes whose expression is dimorphic at E11.5 usually remain
dimorphic at later stages. Each line is a gene, and each column corresponds to a
specific stage and sex. Heatmap: expression signal intensities are shown in red
to yellow to blue indicating high, medium and low expression, respectively.
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To assess whether chromosomal location may correlate with
sex-specific expression, we designed a Matlab computer
program to map on the mouse genome all relevant probe sets
or genes displaying either a male- or a female-specific
expression. Fig. 5 illustrates the chromosomal localization ofFig. 5. Chromosomal map of genes exhibiting sexually dimorphic expression at E
exception of some discrete chromosomal region that host clusters of differentially
represented respectively by red and blue bars. Example of expression profiles of g
similar expression patterns.genes displaying a sexually dimorphic expression at E13.5. At
this stage, male or female overexpressed genes were distributed
widely in the mouse genome; however, we observed some
clusters of male- or female-specific genes. For example, a gene
cluster on a 2.2 megabase region of the long arm of
chromosome 1 contains 31 genes, three of which (e.g., Renin1,
Rassf5 and Prst) exhibited strikingly similar, male-specific
expression patterns. A second gene cluster within a 1.5
megabase region of the distal part of chromosome 7 contains
11 genes, three of which (e.g., Kcnq1 (Hvlqt1), Phlda2 and the
Est AU040576) exhibited a female-specific expression starting
at E12.5. Interestingly, Kcnq1, Phlda2 together with Slc22a11,
Cdkn1c (p57Kip2) and Ascl2 (Mash2) are maternally expressed/
paternally silenced genes clustered in an imprinted domain
associated with the human disease Beckwith–Wiedermann
syndrome (BWS) (Algar et al., 1999; Engel et al., 2000). These
examples point towards common regulatory elements shared
by genes within a given locus to control the expression of
testicular- or ovarian-specific genes.
Dimorphic genes potentially involved in gonadal
differentiation or function
From the set of genes displaying a dimorphic expression, we
chose to further study the gonadal expression of a small
number of these based on their potential involvement in sex
determination and/or gonadal function (Fig. 6). The G-protein-
coupled receptor Grp37 was expressed in both male and female
gonads at E11.5, E12.5 and E13.5; in males, where the gene
was expressed at higher levels, testicular cords were labeled,
consistent with Sertoli cells expression. Cbln1 (Urade et al.,
1991) is a secreted neuropeptide implicated in steroid secretion
(Mazzocchi et al., 1999); Cbln1 expression was male-specific,13.5. Sexually dimorphic genes are scattered throughout the genome with the
expressed genes. Female and male overexpressed genes (4-fold change) are
enes located within a male (B) or a female (C) cluster demonstrated strikingly
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Fig. 6. Expression profiles of potentially relevant genes for gonadal differentiation or function as determined by microarrays and by WISH. (A) Two male (Gpr37 and
Cbln1) and three female (Gpr49, Irx3 and Runx1) overexpressed genes have been selected as examples. (B) Cyclin-dependent kinase inhibitors Cdkn1a, Cdkn1b and
Cdkn1c are overexpressed in developing ovaries. Cdkn1a (p21) exhibited a female-specific expression at E11.5 and E12.5 as determined by microarray and by
WISH. Cdkn1c (p57) expression is reduced in XY gonads and remains relatively constant in XX gonads, while Cdkn1b (p27) became overexpressed in females
starting at E13.5. For the Affymetrix expression profiles, the peak expression level is set as 100%, and the expression levels at other time points are normalized to
percentage of peak levels (% peak). Bars represent the standard deviation.
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onward, suggesting a Leydig cell-specific expression. Gpr49 is
a G-protein-coupled receptor of the LH/FSH family with an
expression restricted to ovarian tissue beginning at E11.5. Irx3
is a transcription factor involved in patterning and differenti-
ation of the nervous system; strong expression was detected
specifically in ovaries, starting at E11.5. Finally, Runx1/AML1
is another transcription factor involved in controlling prolifer-
ation and differentiation; although occurring initially at similar
levels in male and female genital ridges, Runx1 expression
became restricted to the ovaries and mesonephric ducts starting
at E12.5.
One of the earliest morphological changes that occur during
sex determination is a drastic size increase of XY gonads relative
to XX gonads. This variation results from a higher rate of
proliferation that could reflect activation of proliferation in testes
or inhibition of proliferation in ovaries. In general, withdrawal
from the cell cycle by inactivation of cyclin-dependent kinases is
achieved by physical association with cyclin-dependent kinase
inhibitors such as Cdkn1ap21/Cip1/Waf1/Sdi1/Cap20, Cdkn1bp27/Kip1
and Cdkn1cp57/Kip2 (Kiyokawa and Koff, 1998; Sherr and
Roberts, 1999). Sorting the differentially expressed genes
according to gene ontology classification revealed that genes
involved in cell cycle regulation were overexpressed in
developing ovaries. In particular, we found that the cyclin-
dependent kinase inhibitor Cdkn1a (p21) was overexpressed
in XX as compared to XY gonads starting at E11.5 and
E12.5, that Cdkn1b (p27) was upregulated in developingovaries both at E12.5 (2.3-fold) and E13.5 (2.7-fold) and that
Cdkn1c (p57) expression remained strong in ovaries but
decreased in the developing testes (21% reduction at E11.5,
54% at E12.5 and 61% at E13.5) (Fig. 6B). These findings
suggest that female-specific overexpression of Cdkn inhibi-
tors may explain the reduced proliferation and size of ovary
versus testis at the time of sex determination. We hypoth-
esize that Sry may downregulate—either directly or indirect-
ly—the expression of Cdkn inhibitors such as Cdkn1a,
Cdkn1b and Cdkn1c in XY somatic cells, thereby allowing
Sertoli cells to proliferate and divert the XY gonad from the
ovarian fate.
Discussion
The mouse is an attractive model system to investigate the
mammalian male and female genetic programs required for the
uncommitted genital ridge to become either a testis or an ovary.
Indeed, it has been well established that initiation of these
alternative programs depends on the presence or absence of a
single genetic switch, i.e., expression of Sry, and that
morphologic gonadal differentiation occurs during a short time
window of approximately 48 h thereafter. Furthermore, the
cells that are critical for the process of sex determination, i.e.,
the somatic cells of the uncommitted gonad, can be purified
from the genital ridges of embryos carrying a GFP-encoding
transgene under the control of the promoter of the Sf1 gene.
Sf1 is expressed in both male and female genital ridge somatic
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the precursors of the steroidogenic and supporting cell lineages
(Stallings et al., 2002), the latter being essential for the
initiation of the testicular differentiation by Sry (Palmer and
Burgoyne, 1991). Our experimental data have convincingly
established that the GFP+ cell fractions used in our profiling
experiments consisted almost exclusively of somatic Sf1+ cells.
A striking finding in our studies is the scale of both male-
and female-specific genetic programs in gonadal somatic cells.
We found that almost half of the genes (47%) contained on the
Affymetrix microarrays are expressed by the Sf1+ cell
population of which 10% of them exhibited a sexually
dimorphic expression (2306 genes). We have identified more
than 1100 genes that display a sexually dimorphic pattern with
a difference in expression 1.5-fold at E12.5 (592 are
overexpressed in testis and 546 in ovaries). This number
reaches approximately 1900 genes at E13.5 (919 overexpressed
in testes and 1029 in ovaries). Even when the selection criteria
are more stringent, i.e., by increasing the fold changes (see
Table 3), the number of genes exhibiting a sexual dimorphism
remains far above what has previously been identified. Both
the scale and the temporal patterns of sexually dimorphic genes
are a direct consequence of multiple specific genetic programs
that are triggered by the differentiation of Sertoli and Leydig
cell in the testis and granulosa and theca cells in the ovary, all
of these cells expressing Sf1.
Gonads develop as ovaries in the absence of a Y
chromosome, and the prevalent view is that Sry actively
diverts the uncommitted gonad toward the testicular fate via a
male-specific genetic program. The ovarian fate has thus been
considered as the ‘‘default’’ pathway of gonadal differentiation.
But, even if it arises through a ‘‘default’’ pathway, it is obvious
that the ovary must also follow a genetic program of
differentiation (Eicher and Washburn, 1986); however, almost
nothing is known about the ovarian program. Our transcrip-
tome analyses have identified robust genetic programs in both
male and female genital ridges that are initiated prior to the first
morphological changes in the indifferent gonads. Considering
the number of genes with male or female overexpression at
E11.0 and E11.5 (61 and 25 respectively) as well as the average
fold changes in their expression, it appears that the male
genetic program is set in motion slightly earlier and/or more
vigorously than its female counterpart.
One of the most obvious morphological changes following
gonadal differentiation is the size difference between XX and
XY gonads; by E13.5, XY gonads are approximately twice theTable 3
Number of genes (probe sets) classified as sexually dimorphic according to fold ch
Fold Changes E10.5 E11.0 E
Male Female Male Female M
1.5 8 6 11 6 6
2 8 5 8 3 4
3 8 3 7 3 2
4 8 3 7 3 1
5 7 3 7 3 1size of XX gonads. In males, the size increase is due in part to
XY-specific cell migration from the mesonephros and in part
due to an increase in cell proliferation in XY gonads. In
females, this conversely can be viewed as a reduced
proliferative index in the genital ridge. In fact, the earliest
identified physiological difference between XYand XX gonads
is an increase in cell proliferation of Sf1+ cells underlying the
coelomic epithelium in male embryos (Schmahl et al., 2000).
Recent studies (Schmahl and Capel, 2003) have shown that cell
proliferation is necessary for testis determination as inhibition
of proliferation in XY gonads within an 8-h period of gonadal
development (¨E11.2) leads to ovarian differentiation. This
finding suggests that proliferation within a developmental
window is essential to initiate the male pathway. Sry must
therefore either (1) activate genes and signaling pathways
involved in male-specific proliferation in XY gonads or (2)
repress inhibitory signals blocking cell proliferation and
differentiation of supporting lineages. Our observation that
Cdk inhibitors are overexpressed in the developing ovaries
coincident with sex determination and gonadal development
supports the second hypothesis. Reduced proliferation in XX
genital ridges, a female-dependent characteristic, could there-
fore be the result of increased expression of the 3 Cdk
inhibitors (Cdkn1a, b, c), inhibiting cdk activity and causing
Sf1+ cells to cease proliferation. Sry may downregulate—either
directly or indirectly—the expression of Cdkn inhibitors such
as Cdkn1a, Cdkn1b and Cdkn1c in XY somatic cells, thereby
allowing Sertoli cells to proliferate and divert the XY gonad
from the ovarian fate. If correct, this hypothesis requires that
Cdk inhibitors have to be expressed in the supporting cell
lineage of XX gonads at the time of sex determination. Reports
indicate that both Cdkn1a and Cdkn1b are expressed in
granulosa cells and cooperate for the exit of differentiating
granulosa cells from the cell cycle (Jirawatnotai et al., 2003).
Mice lacking Cdnk1b are sterile due to hyperproliferation of
granulosa cells during luteinization (Kiyokawa et al., 1996;
Tong et al., 1998).
For the first time, we have mapped the chromosomal
localization of genes exhibiting ovarian or testicular-specific
expression. If we except the undifferentiated stage at E10.5,
when sexually dimorphic genes are specifically located on X
and Y chromosomes, the genes exhibiting either a testicular or
ovarian-specific profile are generally scattered throughout the
whole genome. Nevertheless, some discrete chromosomal
regions contain clusters of either male or female overexpressed
genes. In some cases, genes located within these clustersanges in expression
11.5 E12.5 E13.5
ale Female Male Female Male Female
1 27 592 546 919 1029
6 15 343 286 562 640
3 6 201 124 298 289
6 5 129 62 235 196
3 4 100 49 182 131
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genes may share common regulatory elements (see Fig. 5 for
clusters on chromosomes 1 and 7). Strikingly, these male- or
female-specific genes are interspaced by other genes within the
cluster that are not sexual dimorphic. In the case of the variant-
specific group of genes on chromosome 7, these genes are part
of a cluster of imprinted genes mapping a synthenic region
corresponding to the human chromosome 11p15.5 whose
dysregulation results in the Beckwith–Wiedermann syndrome
(Koufos et al., 1989).The sexual dimorphic expression of
Kcnq1 , Phlda2 and the Est AU040576 discovered by
chromosome mapping analysis represents an additional layer
of gene regulation together with the regulatory element
controlling imprinting within this cluster. These in silico data
mining analyses could provide information concerning the
identification of genes involved in sexual ambiguities and/or
infertility. For instance, genes with both a sexually dimorphic
expression profile and a chromosomal locus known to be
affected in patients with sexual ambiguity and/or sterility will
represent first choice candidates.
We have analyzed in more detail the expression profile of 5
genes selected for the potential roles in gonadal differentiation
or endocrine functions (see Fig. 6A). Cerebellin1 is a secreted
16-amino-acid peptide widely expressed in the central nervous
system, including the hypothalamus, and in the adrenal medulla
(Satoh et al., 1997). Cbln1 has been reported to stimulate steroid
secretion from adrenal cortex in vivo and in vitro (Albertin
et al., 2000; Mazzocchi et al., 1999). We found that Cbln1 is
upregulated in Leydig cells of the developing testis starting at
E12.5 (see also Menke and Page, 2002), and extrapolation with
its reported function in the adrenal gland suggests that Cbln1
may also regulate steroidogenesis in Leydig cells. Interestingly,
Cbln4, another member of the Cerebellin family, is expressed in
the developing testis but in Sertoli cells starting at E11.5 (Fig. 3
and data not shown). Gpr37 has been selected for its transient
male-specific upregulation at E11.0. Gpr37 encodes an orphan
G-protein-coupled receptor shown to be expressed in brain
tissues and testis (Marazziti et al., 1998). Irx3 belongs to a
homeobox gene family composed of 6 members (Irx1–6)
(Houweling et al., 2001). Irx genes are involved in the
patterning and regionalization of differentiation. Irx3 is known
to direct the neuronal fate of progenitors in the ventral neural
tube (Briscoe et al., 2000). We found that Irx5 is also
specifically expressed in the developing ovary starting at
E11.5 (data not shown). Irx3 and Irx5 genes (chromosome 8)
are separated by 550 kb of intergenic sequences, and thus far no
function has been reported for Irx3 and 5 in the developing
gonad. Another candidate is Gpr49, also known as Lgr5, a G-
protein-coupled receptor belonging to the FSH, LH and TSH
receptor family. Our expression profile demonstrated a female-
specific expression starting at E12.5 (Fig. 6A). In the adult
ovary, Gpr49 is expressed in the follicles (Hermey et al., 1999).
Targeted deletion of Gpr49 in mice leads to neonatal lethality
(Morita et al., 2004) and so far, no report has assessed ovarian
function and development in Gpr49 mutant mice. Finally,
Runx1, also known as AML1, encodes a transcription factor
belonging to a family defined by the runt domain and thatcomprises three members (Runx1, Runx2 and Runx3). Runx1 is
involved in controlling the proliferation and differentiation of
cells during development (Coffman, 2003). In Drosophila, the
Runx1 orthologue (runt) has been implicated in processes such
as sex determination and neurogenesis (Duffy and Gergen,
1991; Duffy et al., 1991). Homozygous Runx1 knockout mice
die at E12.5 from an early block in blood development (Okuda
et al., 1996). So far, no function has been reported for Runx1 in
the developing gonad.
Another study reporting gene expression profiles in male and
female differentiating gonads has been published very recently
(Small et al., 2005). Although conceptually similar, there are a
number of differences in the two studies. The present work used
Sf1+ somatic cells purified from E10.5, E11.0, E11.5, E12.5 and
E13.5 embryos. In contrast, the published study analyzed RNA
prepared from dissected genital ridges at E11.5 (which certainly
included the mesonephros) and whole gonads at later stages
(E12.5, E14.5, E16.5 and E18.5). Our data thus concern the
subset of gonadal cells in which sexually dimorphic gene
expression is initiated and focus more tightly on the 48 h time
window when critical events in gonadal sex determination and
sex differentiation occur. A considerable advantage of working
with Sf1+ cells is to optimize the detection of specific genes
expressed within the population where Sry is thought to be
acting by avoiding dilution by RNAs originating from other cell
populations. Comparing the average signals obtained in the two
studies for the 10 most highly expressed female-specific genes
at E11.5 and E12.5, our results were systematically higher
(between 4- and 9-fold; data not shown). We also detected
sexually dimorphic genes at earlier stages and usually with
greater differences between sexes. For example, female over-
expressed genes such as Fst, Irx3,Wnt4, Cdkn1a and Bmp2 and
male overexpressed genes such as Tesc, Dhh, Fgf9 and Cbln1
were already sexually dimorphic in our study at E11.5, while
such differences did not become detectable until 24 h later in the
whole gonad profiling experiment of Small et al. We also
provide relevant additional data for a number of dimorphic
genes revealed in our study. In particular, WISH on gonads from
normal or busulfan-treated embryos has allowed us to localize
transcripts to specific cell lineages.
Conclusion
This study describes the male and female genetic programs
triggered in the somatic compartment of the developing gonads
during a critical period of sex determination and differentia-
tion. It describes the expression profiles of more that 2300
genes that exhibit either a male or a female-specific expression
pattern and should serve as an expression profile library for
further studies in the field of sex determination, testicular and
ovarian development and functions. Our studies further
provide valuable clues regarding potential candidate genes
involved in mechanisms of normal sex determination, ovarian
and testicular development and their endocrine and reproduc-
tive functions. We identify new molecular markers to trace the
development, differentiation and interactions of the various
cell types of the ovary that should provide the long-needed
S. Nef et al. / Developmental Biology 287 (2005) 361–377376tools to dissect the molecular regulation mediating ovarian
development.
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